Diazyme announced the launch of the FDA 510(k) exempt Beta-Hydroxybutyrate (BHB) Assay for the quantitative determination of Beta-Hydroxybutyrate in human serum or plasma. Diazyme’s enzymatic BHB assay is a dual vial liquid stable reagent that is designed for use on clinical chemistry analyzers.
In diabetic patients, the measurement of BHB along with blood glucose is essential for the assessment of the severity of diabetic coma. It serves as a reliable guide for monitoring the progress of insulin therapy for diabetic ketoacidosis and for any patient presenting to the emergency room with documented hypoglycemia, acidosis, alcohol ingestion, or an unexplained increase in the anion gap.
